New Nasal Covid-19 Vaccine Shows Early Promise in Hamster Studies
Scientists at the Max Delbruck Center for Molecular Medicine in Berlin have made a breakthrough in developing a nasal vaccine against Covid-19. The vaccine, which uses a live but weakened form of the coronavirus, has shown early promise in hamster studies, achieving "sterilizing immunity" and preventing illness.
The vaccine works by boosting mucosal immunity, or immune defenses, in the tissues that line the upper airways, where the virus would typically infect the body. In the study, two doses of the vaccine were found to block the virus from copying itself in the animals' upper airways, resulting in sterilizing immunity and preventing illness.
While this is a promising development, experts caution that more testing is needed before the vaccine can be used in humans. The researchers have partnered with a Swiss company called RocketVax to start phase I clinical trials, but it's unclear when human trials will begin.
Other nasal vaccines are already in use or nearing completion in clinical trials, including ones developed by China and India. However, the effectiveness of these vaccines is not yet known, as studies on their impact have not been published.
In contrast, the German vaccine has shown promise in hamster studies, achieving sterilizing immunity and preventing illness. The researchers believe that the live but weakened virus closely mimics the natural infection process, which may be why it works better than other approaches.
However, experts also note that respiratory infections can be difficult targets for inhaled vaccines, and more work is needed to make these types of vaccines effective. Additionally, live vaccines cannot be taken by everyone, particularly those with compromised immunity.
Despite these challenges, the development of a nasal Covid-19 vaccine is an important step towards preventing the spread of infection. With continued research and testing, it's possible that this approach could lead to a new generation of vaccines that are more effective and accessible to people around the world.
Scientists at the Max Delbruck Center for Molecular Medicine in Berlin have made a breakthrough in developing a nasal vaccine against Covid-19. The vaccine, which uses a live but weakened form of the coronavirus, has shown early promise in hamster studies, achieving "sterilizing immunity" and preventing illness.
The vaccine works by boosting mucosal immunity, or immune defenses, in the tissues that line the upper airways, where the virus would typically infect the body. In the study, two doses of the vaccine were found to block the virus from copying itself in the animals' upper airways, resulting in sterilizing immunity and preventing illness.
While this is a promising development, experts caution that more testing is needed before the vaccine can be used in humans. The researchers have partnered with a Swiss company called RocketVax to start phase I clinical trials, but it's unclear when human trials will begin.
Other nasal vaccines are already in use or nearing completion in clinical trials, including ones developed by China and India. However, the effectiveness of these vaccines is not yet known, as studies on their impact have not been published.
In contrast, the German vaccine has shown promise in hamster studies, achieving sterilizing immunity and preventing illness. The researchers believe that the live but weakened virus closely mimics the natural infection process, which may be why it works better than other approaches.
However, experts also note that respiratory infections can be difficult targets for inhaled vaccines, and more work is needed to make these types of vaccines effective. Additionally, live vaccines cannot be taken by everyone, particularly those with compromised immunity.
Despite these challenges, the development of a nasal Covid-19 vaccine is an important step towards preventing the spread of infection. With continued research and testing, it's possible that this approach could lead to a new generation of vaccines that are more effective and accessible to people around the world.